Haihe pharmaceutical
WebHaiHe Biopharma’s Profile, Revenue and Employees. HaiHe Biopharma is a biopharmaceutical company that discovers, develops and commercializes anti-tumor … WebAug 29, 2024 · The SPC upheld the Beijing IP Court ruling that Wenzhou Haihe Pharmaceutical Co., Ltd.’s application for marketing authorization for a generic form of “Aidecalcidol Soft Capsule” did not ...
Haihe pharmaceutical
Did you know?
WebHaiHe Biopharma focuses on the discovery, development and commercialization of anti-tumor drugs. Use the CB Insights Platform to explore HaiHe Biopharma's full profile. ... WebJun 1, 2024 · Wenzhou Haihe Pharmaceutical Co., Ltd ('Haihe Pharma'), the Beijing Intellectual Property Court held that the generic drug involved did not fall within the scope of protection of the Plaintiff's patent. (Patent linkage refers to the relationship between the market approval for a generic drug and the patent status of its branded equivalent.)
WebHuagai Capital Website: http://www.hgcapital.cn BioCentury Jul 22, 2024 Emerging Company Profile PAQ: small molecules for autophagy-dependent degradation ...one to two additional compounds against different targets. Huagai Capital ... ...6Funds raised: $34 millionInvestors: Sherpa Healthcare Partners, Huagai Capital ... WebHaihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor … Haihe Biopharma is an innovation-driven biotechnology company in China … Out-licensing or Co-development. Many of our investigational products are … Profile: Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with … Shanghai, China, April, 7, 2024 -- Shanghai Haihe Biopharma Co., Ltd (referred as … Haihe Biopharma hopes to motivate and develop outstanding talent and support …
WebJun 6, 2024 · Subjects first receive a single-dose of 0.75 μg reference eldecalcitol soft capsule (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the first treatment … WebAug 27, 2024 · NEW YORK ─ Amoy Diagnostics of Xiamen, China, said on Thursday that it has inked an agreement with Shanghai-based Haihe Pharmaceutical to codevelop a companion diagnostic test for the Japanese market. The CDx, based on AmoyDx's PCR platform, is being developed for use with Haihe's MET kinase inhibitor Glumetinib …
http://jolt.law.harvard.edu/digest/chinas-supreme-peoples-court-issued-first-patent-linkage-decision
WebNov 2, 2024 · PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT (WJOG6410L; University Hospital Medical Information Network Clinical Trials Registry: UMIN000006252), a randomized, open-label, phase III study, included patients … bloodline of the dragonWebOct 28, 2024 · PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis. MATERIALS AND METHODS We studied … free crochet men hat patternsWeb抗肿瘤辅助药有哪些公司？天眼查为您提供抗肿瘤辅助药相关企业信息，让您对抗肿瘤辅助药相关企业的融资信息、成立时间、所属地和产品详情有一个全面的认识，想查询更多抗肿瘤辅助药公司就来天眼查官网！ free crochet men\u0027s hat and scarf patterns